Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?
Jorgensen
C
C
Immuno-rheumatology Department, CHU Lapeyronie, Montpellier, France.
Apparailly
F
F
Sany
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016753:Interleukin-10 / Q000627:therapeutic use; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016753:Interleukin-10; D018121:Receptors, Cytokine; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors